396 related articles for article (PubMed ID: 24585509)
41. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
42. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
43. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Perry CM
Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
[TBL] [Abstract][Full Text] [Related]
44. Vitamin D supplementation for chronic liver diseases in adults.
Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
[TBL] [Abstract][Full Text] [Related]
45. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
46. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
47. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.
Simin M; Brok J; Stimac D; Gluud C; Gluud LL
Aliment Pharmacol Ther; 2007 May; 25(10):1153-62. PubMed ID: 17451561
[TBL] [Abstract][Full Text] [Related]
48. Ribavirin monotherapy for chronic hepatitis C.
Brok J; Gluud L; Gluud C
Cochrane Database Syst Rev; 2005 Oct; (4):CD005527. PubMed ID: 16235408
[TBL] [Abstract][Full Text] [Related]
49. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis.
Kim AI; Dorn A; Bouajram R; Saab S
HIV Med; 2007 Jul; 8(5):312-21. PubMed ID: 17561878
[TBL] [Abstract][Full Text] [Related]
50. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
51. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis.
Simonetti RG; Perricone G; Nikolova D; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD004039. PubMed ID: 31251387
[TBL] [Abstract][Full Text] [Related]
52. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
53. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
54. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S
J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633
[TBL] [Abstract][Full Text] [Related]
55. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Sulkowski M; Pol S; Mallolas J; Fainboim H; Cooper C; Slim J; Rivero A; Mak C; Thompson S; Howe AY; Wenning L; Sklar P; Wahl J; Greaves W;
Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
[TBL] [Abstract][Full Text] [Related]
56. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
57. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C.
Zaman A; Fennerty MB; Keeffe EB
Aliment Pharmacol Ther; 2003 Oct; 18(7):661-70. PubMed ID: 14510739
[TBL] [Abstract][Full Text] [Related]
58. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
[TBL] [Abstract][Full Text] [Related]
59. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation.
Gurusamy KS; Tsochatzis E; Davidson BR; Burroughs AK
Cochrane Database Syst Rev; 2010 Dec; (12):CD006573. PubMed ID: 21154370
[TBL] [Abstract][Full Text] [Related]
60. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U; Sroczynski G; Rossol S; Wasem J; Ravens-Sieberer U; Kurth BM; Manns MP; McHutchison JG; Wong JB; ;
Gut; 2003 Mar; 52(3):425-32. PubMed ID: 12584228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]